靶向CD38的α发射体砹-211可根除播散性多发性骨髓瘤模型
多发性骨髓瘤患者中约75%无法达到MRD阴性(≤10⁻⁵),而MRD阴性预示显著更长生存。本研究将α发射体砹-211(²¹¹At)偶联抗CD38单抗,在播散性疾病模型(模拟低负荷MRD)中单次24-45 µCi使50%-80%小鼠获得持续缓解和长期生存(>150天),毒性短暂轻微。
要点
- ²¹¹At-CD38在低负荷播散模型中可根除残留骨髓瘤细胞。
- 单次24-45 µCi使50%-80%小鼠长期生存超过150天。
- 计划临床试验中联合ASCT预处理可能改善移植结局。
核心结论
- ²¹¹At-CD38在低疾病负荷(包括MRD)背景下有潜力消除残留骨髓瘤细胞克隆。
研究设计与样本
- 研究将α发射体²¹¹At偶联抗CD38单抗,在骨髓瘤裸鼠模型(大负荷异种移植和播散性疾病模型)中评估疗效。
主要发现
- 在大负荷异种移植模型中,单次15-45 µCi的²¹¹At-CD38使中位生存期至少翻倍(P < .003),但无小鼠达到完全缓解,全部在75天内死亡。
- 在模拟低负荷MRD的播散性疾病模型中,3项研究显示单次24-45 µCi的²¹¹At-CD38使50%-80%小鼠获得持续缓解和长期生存(>150天),而未治疗小鼠全部在20-55天内死亡(P < .0001)。
- 治疗毒性短暂且轻微。
关键数值与推荐
- 约75%的多发性骨髓瘤患者一线治疗后无法达到MRD阴性(≤10⁻⁵)。
- 在大负荷模型中,单次15-45 µCi的²¹¹At-CD38使中位生存期至少翻倍(P < .003)。
- 在播散模型中,单次24-45 µCi的²¹¹At-CD38使50%-80%小鼠长期生存>150天(P < .0001)。
临床怎么用
- ²¹¹At-CD38可能用于低疾病负荷(包括MRD)的多发性骨髓瘤患者,以清除残留细胞。
- 计划在自体干细胞移植(ASCT)预处理方案中加入²¹¹At-CD38,可能改善ASCT结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Minimal residual disease (MRD) has become an increasingly prevalent and important entity in multiple myeloma (MM). Despite deepening responses to frontline therapy, roughly 75% of MM patients never become MRD-negative to ≤10-5, which is concerning because MRD-negative status predicts significantly longer survival. MM is highly heterogeneous, and MRD persistence may reflect survival of isolated single cells and small clusters of treatment-resistant subclones. Virtually all MM clones are exquisitely sensitive to radiation, and the α-emitter astatine-211 (211At) deposits prodigious energy within 3 cell diameters, which is ideal for eliminating MRD if effectively targeted. CD38 is a proven MM target, and we conjugated 211At to an anti-CD38 monoclonal antibody to create an 211At-CD38 therapy. When examined in a bulky xenograft model of MM, single-dose 211At-CD38 at 15 to 45 µCi at least doubled median survival of mice relative to untreated controls (P < .003), but no mice achieved complete remission and all died within 75 days. In contrast, in a disseminated disease model designed to reflect low-burden MRD, 3 studies demonstrated that single-dose 211At-CD38 at 24 to 45 µCi produced sustained remission and long-term survival (>150 days) for 50% to 80% of mice, where all untreated mice died in 20 to 55 days (P < .0001). Treatment toxicities were transient and minimal. These data suggest that 211At-CD38 offers the potential to eliminate residual MM cell clones in low-disease-burden settings, including MRD. We are optimistic that, in a planned clinical trial, addition of 211At-CD38 to an autologous stem cell transplant (ASCT) conditioning regimen may improve ASCT outcomes for MM patients.
引用
- O'Steen S, Comstock ML, Orozco JJ, et al. The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model. Blood. 2019. PMID: 31395601. doi:10.1182/blood.2019001250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。